Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 6.77 Billion | USD 13.58 Billion | 8.04% | 2023 |
The global Somatostatin Analogs market size was worth around USD 6.77 billion in 2023 and is predicted to grow to around USD 13.58 billion by 2032 with a compound annual growth rate (CAGR) of roughly 8.04% between 2024 and 2032.
The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Somatostatin Analogs market on a global and regional level.
Somatostatin analogs are medications that stop too many hormones in your body. Many neuroendocrine tumors (NETs) make large quantities of hormones that cause a group of symptoms called carcinoid syndrome. In people with carcinoid syndrome, somatostatin analogs are a possible treatment. There are a number of things Somatostatin does. A variety of hormones such as insulin and gut hormones are slowed down or halted. It also regulates the stomach and intestine emptying. A somatostatin analog is a man-made somatostatin (synthetic) form. This slows hormone production, especially growth hormone and serotonin. It helps control carcinoid syndrome symptoms such as diarrhea and skin flushing. It can shorten the NET as well.
Some of the factors driving the growth of the demand for somatostatin analogs are growing R&D initiatives and the release of novel drug therapies. For starters, Novartis AG introduced Signifor (Pasireotide) in 2012 to treat Cushing's syndrome and acromegaly in 2014. Another key contributing factor to overall market growth is the presence of favorable government insurance policies & schemes for rare disease patients. For example, multiple government healthcare agencies in the U.S. and Europe, such as the National Institutes of Health (NIH) and the National Center of Advancing Translational Sciences (NCATS), provide affordable rare disease medicines.
The study includes drivers and restraints for the Somatostatin Analogs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Somatostatin Analogs market on a global level. In order to give the users of this report a comprehensive view of the Somatostatin Analogs market, we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein indication, type, and regional segments are benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the Somatostatin Analogs market by segmenting the market based on indication, type, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.
Based on type, the market is segmented into octreotide, lanreotide, and pasireotide. Due to its various therapeutic applications such as acromegaly, carcinoid tumors, and vasoactive intestinal peptide tumors, octreotide dominated the overall category segment in 2023.
Based on indication, the market is segmented into acromegaly, NETs, and others. In 2023, blood transfusion therapy held the largest market share. Acromegaly is projected to be the largest segment in 2023 and the fastest growing segment over the forecast period. Increasing acromegaly awareness coupled with the availability of effective treatment options is considered to be the major factor driving growth in the segment. For example, in November 2018, Acromegaly Awareness Day was held in Canada, providing various acromegaly information along with the treatment options available and their benefits.
Report Attributes | Report Details |
---|---|
Report Name | Somatostatin Analogs Market |
Market Size in 2023 | USD 6.77 Billion |
Market Forecast in 2032 | USD 13.58 Billion |
Growth Rate | CAGR of 8.04% |
Number of Pages | 130 |
Key Companies Covered | Camurus AB, Chiasma Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Ipsen Pharma, Midatech Pharma PLC, Novartis AG, Peptron, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Teva Pharmaceuticals Inc amongst others. |
Segments Covered | By Type, By Indication By End-Use and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries such as the US, Canada, Germany, UK, France, China, Japan, India, GCC countries, Brazil. North America dominated the market. The initial factors responsible for local growth are expected to be the high prevalence of acromegaly and NETs.
Key players within the global Somatostatin Analogs market include:
Global Somatostatin Analogs Market: Indication Segment Analysis
Global Somatostatin Analogs Market: Type Segment Analysis
Global Somatostatin Analogs Market: Regional Segment Analysis
FrequentlyAsked Questions
Somatostatin analogs are synthetic drugs designed to mimic the action of somatostatin, a hormone that inhibits the release of several other hormones, including growth hormone, insulin, and glucagon.
According to study, the Somatostatin Analogs Market size was worth around USD 6.77 billion in 2023 and is predicted to grow to around USD 13.58 billion by 2032.
The CAGR value of Somatostatin Analogs Market is expected to be around 8.04% during 2024-2032.
North America has been leading the Somatostatin Analogs Market and is anticipated to continue on the dominant position in the years to come.
The Somatostatin Analogs Market is led by players like Camurus AB, Chiasma Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Ipsen Pharma, Midatech Pharma PLC, Novartis AG, Peptron Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Teva Pharmaceuticals Inc, amongst others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed